reports
- Carole Braudeau
- Stephane Beyazian
- Stephane Beyazian
- Michael B. Schäfer
- Stephan Wulf
Bayer : FY guidance confirmed after solid Q1 results – Pharma better, ...
>EBITDA decline less pronounced than feared - At a group level, Bayer’s Q1 sales of € 13.8bn (-4.3%), was below our (€ 14.0bn) and the consensus estimates (€ 14.1bn), the group’s EBITDA of € 4,412m (-1.3%) came in stronger than we expected (€ 4,188m) and was 6.4% above the consensus. The group’s EBITDA decline vs Q1 2023 was driven by the Crop Science divisions, where a decrease in glyphosate-based herbicides and cost inflation weighed on earnings. On the back of the ...
- Carole Braudeau
Morning Crédit 14/05/2024
Iliad abonde les obligations Iliad Holding 2031 à hauteur de 150 m EUR et 200 m USD Grifols : S&P confirme le rating corporate B avec une perspective stable (vs. B/cw negative) Delivery Hero : cession de foodpanda à Uber pour 950 m USD + augmentation de capital réservée de 300 m USD>...
- Rafael Bonardell
- Research Department
INFORME DIARIO 14 MAYO + RDOS. ESPAÑA Y EUROPA 1T’24. PREVIEWS (ANÁLIS...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, COLONIAL, FERROVIAL, GRIFOLS, LOGISTA, NH HOTELES, UNICAJA. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Jornada de transición en las bolsas En una sesión sin referencias macroeconómicas y con la campaña de resultados com...
Charles River Laboratories Announces First-Quarter 2024 Results
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, organic revenue decreased 3.3%. On a segment basis, both the ...
Charles River Launches Viral Vector Reference Materials to Streamline ...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior and capsid ratios and high vector genome concentration (GC/mL), plus five products, available wi...
Moody's Ratings affirms Charles River's Ba1 CFR, outlook stable
Moody's Ratings (Moody's) affirmed the ratings of Charles River Laboratories International Inc. ("Charles River"). The affirmed ratings include the Ba1 Corporate Family Rating, the Ba1-PD Probability of Default Rating, as well as the Baa3 senior secured ratings, and the Ba2 senior unsecured ratings....
Charles River Laboratories Achieves 100% Renewable Electricity Usage G...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date. In 2020, Charles River became one of the first 300 members of , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030. Today, Charles River joins a small group of leading companies that have achieved this goal organization-wide in accordance with RE10...
Charles River Laboratories Launches Alternative Methods Advancement Pr...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing. The initiative aims to drive the new standard for drug discovery and development and encapsulates the Company’s initial $200 million investment over the past four years and its five-year goal of investing an additional $300 million. This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce...
Charles River Laboratories Schedules First-Quarter 2024 Earnings Relea...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharma...
Charles River and Deciphex Launch Patholytix Foresight, a Transformati...
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing deci...
Hybridan Small Cap Feast - 9 April 2024
9th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Helix Exploration (HEX.L) a helium exploration company with operations in Montana, USA announces admission of its Ordinary Shares to trading on the AIM market of the London Stock Exchange. An Oversubscribed placing with book of demand over £22m to raise gross proceeds of...
Charles River Announces Rare Disease Gene Therapy Collaboration with A...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caused by cilia dysfunction, which is a group of complex disorders caused by genetic mutations that result in defective or dy...
- Carole Braudeau
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.